Bli medlem
Bli medlem

Du är här

2016-03-04

Medivir: Medivir's Nomination Committee proposes new Board of Directors ahead of 2016 AGM

Press release, 3 March 2016

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today
announced the Nomination Committee's proposal for a new Board of
Directors that will be submitted to the 2016 Annual General Meeting.
The 2015-2016 Nomination Committee comprises representatives of the
company's three largest shareholders at the end of the third quarter
of 2015 who have accepted a seat on the Nomination Committee, and the
Chairman of the Board. The composition of the 2015-2016 Nomination
Committee was as follows:

· Maria Rengefors, Chairman of the Nomination Committee,
representing Nordea Fonder

· Anders Hallberg, representing HealthInvest Partners AB
· Bo Öberg, representing the class A shareholders
· Birgitta Stymne Göransson, Chairman of the Board of Medivir AB
The Nomination Committee has agreed, ahead of the upcoming 2016 Annual
General Meeting, to propose that a new Board of Directors be
appointed by means of the re-election of the Board's existing
Members, namely Anders Ekblom, Anders Hallberg, Johan Harmenberg,
Helena Levander and Anna Malm Bernsten, and the new election of one
Member, namely Thomas Axelsson. The Committee also proposes the
election of Anna Malm Bernsten as Chairman of the Board.

Bertil Samuelsson and Birgitta Stymne Göransson have declined
re-election.

Thomas Axelsson, born 1959. Thomas has studied industrial engineering
at Linköping Technical Institute and is CEO of Vitrolife AB since
2011. He is a also Member of the Board of MedCap AB. Thomas is a
former CEO of Stille AB and Artema AB and has worked for a number of
companies in the life sciences and medical technology sectors,
including as a Business Area Manager at Baxter. He has also been on
the Board of several Life science companies including Chairman of the
Boards of SBL Vaccin AB, Neoventa Medical AB, Stille AB and Airsonett
AB.

For more information please contact:
Maria Rengefors, Nordea Fonder, +46 10-1565 674.
Medivir is required under the Securities Markets Act to make the
information in this press release public.

The information was submitted for publication at 9.00 CET on 3 March
2016.

About Medivir
Medivir is a research based pharmaceutical company with a research
focus on infectious diseases and oncology. We have a leading
competence within protease inhibitor design and nucleotide/nucleoside
science and we are dedicated to develop innovative pharmaceuticals
that meet great unmet medical need. Our commercial organization
provides a portfolio of specialty care pharmaceuticals on the Nordic
market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

-----------------------------------------------------------
http://news.cision.com/medivir/r/medivir-s-nomination-committee-proposes...
http://mb.cision.com/Main/652/9928602/484562.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.